Hyperfine (NASDAQ:HYPR) Posts Quarterly Earnings Results, Meets Estimates

Hyperfine (NASDAQ:HYPR) released its quarterly earnings results on Thursday. The company reported ($0.09) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.09), FiscalAI reports. Hyperfine had a negative net margin of 210.75% and a negative return on equity of 99.81%. The business had revenue of $3.90 million during the quarter, compared to analyst estimates of $4.13 million.

Here are the key takeaways from Hyperfine’s conference call:

• Revenue rose 45% year over year to $3.9 million in Q2, while system sales increased 50% to 12 units; first-half revenue reached $7.8 million.
• Gross margin remained above 50% for the fourth consecutive quarter at 50.7%, while first-half cash burn improved approximately 9% year over year to $16.6 million.
• Management reiterated 2026 revenue guidance of $20 million to $22 million, gross margin of 50% to 55%, cash burn of $26 million to $28 million, and cash runway extending into 2028.
• Growth is broadening across hospitals and IDNs, neurology offices, and international markets; the company cited initial large-IDN adoption, more than a dozen office placements, and first European Model 2 sales.
• Hyperfine remains loss-making, reporting a $9.3 million quarterly net loss, and its stronger cash position partly reflects $10.6 million raised through its ATM program, which may create shareholder dilution.

Hyperfine Stock Performance

Shares of NASDAQ HYPR traded down $0.03 during trading on Friday, reaching $0.95. The stock had a trading volume of 904,666 shares, compared to its average volume of 732,139. The stock has a market cap of $94.80 million, a PE ratio of -2.51 and a beta of 1.42. Hyperfine has a one year low of $0.85 and a one year high of $2.22. The firm’s 50 day moving average price is $1.23 and its two-hundred day moving average price is $1.25. The company has a debt-to-equity ratio of 0.38, a quick ratio of 4.90 and a current ratio of 5.52.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the business. EP Wealth Advisors LLC bought a new stake in Hyperfine during the fourth quarter worth approximately $34,000. XTX Topco Ltd lifted its stake in Hyperfine by 47.9% in the fourth quarter. XTX Topco Ltd now owns 80,735 shares of the company’s stock valued at $79,000 after buying an additional 26,165 shares during the period. Millennium Management LLC bought a new stake in Hyperfine in the fourth quarter valued at approximately $55,000. Bridgeway Capital Management LLC raised its stake in Hyperfine by 50.2% during the 4th quarter. Bridgeway Capital Management LLC now owns 119,700 shares of the company’s stock worth $117,000 after buying an additional 40,000 shares during the period. Finally, Walleye Capital LLC bought a new position in Hyperfine during the fourth quarter worth about $212,000. Institutional investors and hedge funds own 15.03% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have weighed in on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Hyperfine in a research note on Friday, July 17th. B. Riley Financial reaffirmed a “buy” rating on shares of Hyperfine in a research report on Wednesday, May 13th. Finally, BTIG Research began coverage on Hyperfine in a research note on Wednesday, April 29th. They set a “buy” rating and a $2.00 target price for the company. Three investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $1.78.

About Hyperfine

Hyperfine, Inc (NASDAQ: HYPR) is a medical technology company focused on expanding access to advanced neuroimaging through its portable magnetic resonance imaging (MRI) system. The company’s flagship product, Swoop®, is designed to enable bedside MRI scanning in a wide range of clinical environments, including emergency departments, intensive care units and outpatient clinics. By leveraging a compact, high-performance permanent magnet and a custom-designed gradient system, Hyperfine aims to reduce the logistical and financial barriers associated with traditional, large-scale MRI installations.

The Swoop system features a lightweight, wheeled design that can be maneuvered directly to a patient’s bedside, allowing clinicians to conduct diagnostic imaging without the need to transport critically ill or immobile patients.